TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2272007

Group type: EXPERIMENTAL
Intervention: Exercise program (n = 69): walking or jogging for 30 min, 3 times per week for one year
Number of subjects: 138

Group type: COMPARATOR
Intervention: Control group (n = 69)
Number of subjects: 138
Study: 6793418

Group type: EXPERIMENTAL
Intervention: Ro 8‐8427 (Phenoro) at a daily dose of 100 mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 29053219

Group type: EXPERIMENTAL
Intervention: Chewing gum (CG)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Non-chewing gum (NG)
Number of subjects: 158
Study: 26682793

Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 876

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 876

Group type: EXPERIMENTAL
Intervention: Both beta-blockers
Number of subjects: 876
Study: 25831603

Group type: EXPERIMENTAL
Intervention: Fluoride group (non-sucrose food supplement containing fluoride, 1,500 μg/l per dose)
Number of subjects: 228

Group type: COMPARATOR
Intervention: Control group (non-sucrose food supplement without fluoride)
Number of subjects: 228
Study: 22218164

Group type: EXPERIMENTAL
Intervention: Adaptive regulation strategies (accept, reappraise)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No specific regulation instructions
Number of subjects: 0
Study: 20022869

Group type: EXPERIMENTAL
Intervention: 2DTEE planimetry method
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 3DTEE method
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 2DTEE short-axis images during systole
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 2DTEE and 3DTEE methods
Number of subjects: 70
Study: 17666600

Group type: EXPERIMENTAL
Intervention: IV ferric carboxymaltose (less than or equal to 1,000 mg over 15 minutes, repeated weekly to achieve a total calculated replacement dose)
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: IV ferric carboxymaltose
Number of subjects: 352

Group type: COMPARATOR
Intervention: Oral iron (ferrous sulfate 325 mg orally thrice daily for 6 weeks)
Number of subjects: 352
Study: 16110231

Group type: EXPERIMENTAL
Intervention: Oral amino acids (12 g/day)
Number of subjects: 100
Study: 12177099

Group type: EXPERIMENTAL
Intervention: Fulvestrant 250 mg once-monthly intramuscular injection
Number of subjects: 451

Group type: COMPARATOR
Intervention: Anastrozole 1 mg oral dose
Number of subjects: 451
Study: 9870019

Group type: EXPERIMENTAL
Intervention: Internal transcatheter cardioversion
Number of subjects: 40

Group type: COMPARATOR
Intervention: External cardioversion
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cross-over to internal cardioversion
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cross-over to external cardioversion
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 40

Group type: COMPARATOR
Intervention: Internal vs External cardioversion
Number of subjects: 40
Study: 7986410

Group type: EXPERIMENTAL
Intervention: Healthy long-term HIV-positives (HLP)
Number of subjects: 588

Group type: COMPARATOR
Intervention: Progressors (men with HIV seroconversion prior to 1983 but with AIDS or CD4+ counts < 200 x 10(6)/l)
Number of subjects: 588

Group type: COMPARATOR
Intervention: HLP
Number of subjects: 588
Study: 2686658

Group type: EXPERIMENTAL
Intervention: Tromantadine
Number of subjects: 120

Group type: COMPARATOR
Intervention: Aciclovir
Number of subjects: 120
Study: 31941523

Group type: EXPERIMENTAL
Intervention: Capecitabine plus Radium-223 (Xofigo™)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 28871621

Group type: EXPERIMENTAL
Intervention: Systolic blood pressure (SBP) decrease during the first 24 hours from randomization
Number of subjects: 1257
Study: 28241780

Group type: EXPERIMENTAL
Intervention: Standard coagulation tests-based transfusion strategy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thromboelastometry-based transfusion strategy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Restrictive transfusion strategy
Number of subjects: 0
Study: 25733000

Group type: EXPERIMENTAL
Intervention: 1.8 mg pegfilgrastim
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: 3.6 mg pegfilgrastim
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: 6.0 mg pegfilgrastim
Number of subjects: 87
Study: 23589326

Group type: EXPERIMENTAL
Intervention: Nutrition-based shared medical appointment (SMA), three 90-minute sessions
Number of subjects: 94

Group type: COMPARATOR
Intervention: Individualized counseling (control group)
Number of subjects: 94
Study: 21534714

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX‐A) treatment followed by NeuroMuscular Retraining Therapy (NMRT)
Number of subjects: 20
Study: 19331489

Group type: EXPERIMENTAL
Intervention: Topiramate (200 or 300 mg)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 16677331

Group type: COMPARATOR
Intervention: 1100 ppmF, NaF (group A)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: 1100 ppmF, NaF and chlorhexidine 0.95% (group B)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Chlorhexidine 0.95% (group C)
Number of subjects: 83
Study: 15117007

Group type: EXPERIMENTAL
Intervention: Participants with strong protected values (PVs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Participants with few protected values (PVs)
Number of subjects: 0
Study: 11246614

Group type: EXPERIMENTAL
Intervention: 3 MU IFN t.i.w. for 1 year (Group 1)
Number of subjects: 538

Group type: EXPERIMENTAL
Intervention: 3 MU IFN t.i.w. for 1 year (Group 2)
Number of subjects: 538

Group type: EXPERIMENTAL
Intervention: 5 MU IFN t.i.w. for 1 year (Group 3)
Number of subjects: 538

Group type: EXPERIMENTAL
Intervention: 3 MU IFN t.i.w. for 1 year (Group 4)
Number of subjects: 538

Group type: EXPERIMENTAL
Intervention: 5 MU IFN t.i.w. for 1 year (Group 5)
Number of subjects: 538

Group type: EXPERIMENTAL
Intervention: 3 MU IFN t.i.w. for 1 year (Group 6)
Number of subjects: 538

Group type: EXPERIMENTAL
Intervention: 5 MU IFN daily for 2 months followed by 5 MU t.i.w. for a further 10 months (Group 7)
Number of subjects: 538
Study: 9307535

Group type: EXPERIMENTAL
Intervention: Extra-amniotic saline
Number of subjects: 121

Group type: COMPARATOR
Intervention: Intra-amniotic prostaglandin
Number of subjects: 121
Study: 8039154

Group type: EXPERIMENTAL
Intervention: Pulsed high dose chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dose intensity regimens
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Peripheral blood progenitor cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Genetically engineered hematopoietic growth factors
Number of subjects: 0
Study: 2553568

Group type: EXPERIMENTAL
Intervention: PK 11195 (10 mg IV)
Number of subjects: 10

Group type: COMPARATOR
Intervention: PK 11195 (100 mg oral)
Number of subjects: 10

Group type: COMPARATOR
Intervention: PK 11195 (200 mg oral)
Number of subjects: 10

Group type: COMPARATOR
Intervention: PK 11195 (400 mg oral)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (oral)
Number of subjects: 10
Study: 59855

Group type: EXPERIMENTAL
Intervention: Ethamsylate treatment (Dicynene)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 31705384

Group type: EXPERIMENTAL
Intervention: Behavioral, Academic, and Social Engagement (BASE) classroom management model training for teachers
Number of subjects: 2925
Study: 30850441

Group type: EXPERIMENTAL
Intervention: 12-week aerobic training program using recombinant exercise bicycles, 3 times per week
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control period (no aerobic training)
Number of subjects: 40
Study: 28228578

Group type: EXPERIMENTAL
Intervention: GSK249320
Number of subjects: 134

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study: 24800582

Group type: EXPERIMENTAL
Intervention: Spironolactone 100 mg/d and Furosemide 40 mg/d, adjusted every four days to a maximum of 400 mg/d and 160 mg/d respectively
Number of subjects: 80

Group type: COMPARATOR
Intervention: Spironolactone 100 mg/d and Furosemide 40 mg/d, adjusted every seven days to a maximum of 400 mg/d and 160 mg/d respectively
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Observation group
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study: 22673139

Group type: EXPERIMENTAL
Intervention: Hib-MenC-TT group
Number of subjects: 268

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: DTaP-IPV recipients
Number of subjects: 268

Group type: COMPARATOR
Intervention: DTaP-IPV-Hib recipients
Number of subjects: 268
Study: 20337633

Group type: EXPERIMENTAL
Intervention: DMARDs (10 patients with methotrexate and 10 with adalimumab)
Number of subjects: 25
Study: 18568687

Group type: EXPERIMENTAL
Intervention: Aggressive antihypertensive combination treatment
Number of subjects: 10173
Study: 16082639

Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 6-DVU STIR score
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Status score
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Change score
Number of subjects: 31
Study: 12430666

Group type: EXPERIMENTAL
Intervention: WBC-reduced RBCs and platelets
Number of subjects: 2780

Group type: COMPARATOR
Intervention: Unmodified blood components
Number of subjects: 2780
Study: 10355233

Group type: EXPERIMENTAL
Intervention: Masked rhyming prime
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rhyme priming effect
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phonological (rhyme detection) task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phonological and semantic priming effects
Number of subjects: 0
Study: 8541683

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy with recombinant tissue‐type plasminogen activator for up to 4 hours followed by angioplasty (n = 11)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Angioplasty alone (n = 9)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy (n = 4 with limb-threatening ischemia)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 20
Study: 2790862

Group type: EXPERIMENTAL
Intervention: Fluoride toothpastes (sodium fluoride and sodium monofluorophosphate with calcium glycerophosphate)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Sodium monofluorophosphate containing toothpaste
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control toothpaste (fluoride-free)
Number of subjects: 22
Study: 754991

Group type: EXPERIMENTAL
Intervention: Negative pressure of -49.1 kPa (-0.5 kp/cm2)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Negative pressure of -78.5 kPa (-0.8 kp/cm2)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 167
Study: 31271875

Group type: EXPERIMENTAL
Intervention: Cocoa extract (600 mg/d cocoa flavanols)
Number of subjects: 2262

Group type: EXPERIMENTAL
Intervention: Multivitamin
Number of subjects: 2262

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 2262
Study: 28256915

Group type: EXPERIMENTAL
Intervention: 50 mg dehydroepiandrosterone (DHEA)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 26048317

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of tirofiban at 0.075μg/kg/min for 24h
Number of subjects: 104
Study: 22717993

Group type: EXPERIMENTAL
Intervention: Dual-processing instruction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Undirected instruction
Number of subjects: 0
Study: 21714879

Group type: EXPERIMENTAL
Intervention: LigaSure™ dissection technique
Number of subjects: 102

Group type: COMPARATOR
Intervention: Conventional dissection technique
Number of subjects: 102
Study: 19267951

Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 774

Group type: COMPARATOR
Intervention: Conventional low-fat diet (Control)
Number of subjects: 774

Group type: EXPERIMENTAL
Intervention: Mediterranean diet in diabetic patients
Number of subjects: 774
Study: 16634720

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 14685863

Group type: EXPERIMENTAL
Intervention: DWN
Number of subjects: 8

Group type: COMPARATOR
Intervention: FLA
Number of subjects: 8
Study: 11762686

Group type: EXPERIMENTAL
Intervention: Exercise (3 30-minute classes per week for 23 weeks)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (no exercise intervention)
Number of subjects: 50
Study: 9640081

Group type: EXPERIMENTAL
Intervention: Salmon calcitonin (CT) at a dose of 100 i.v./days s.c. for three days in patients with chronic moderate bronchial asthma
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (psychological saline) in patients with mild bronchial asthma
Number of subjects: 24
Study: 8330463

Group type: EXPERIMENTAL
Intervention: Transnasal butorphanol (2 mg on day 1, followed by 1, 2, and 4 mg every 6 hours on days 2-6, 7-11, and 12-16)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 3106095

Group type: EXPERIMENTAL
Intervention: Oxytocin (OT)
Number of subjects: 35

Group type: COMPARATOR
Intervention: TRH alone
Number of subjects: 35

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 35
Study: 31479083

Group type: COMPARATOR
Intervention: Computerized Cognitive Training (CCT)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Tai Chi (TC)
Number of subjects: 96
Study: 29945954

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) - single infusion of 0.8 g/kg
Number of subjects: 206

Group type: COMPARATOR
Intervention: Careful observation
Number of subjects: 206
Study: 26894413

Group type: EXPERIMENTAL
Intervention: Palbociclib plus letrozole (letrozole 2.5 mg daily + palbociclib 125 mg once daily for 3 weeks followed by 1 week off)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Letrozole alone (2.5 mg daily)
Number of subjects: 0
Study: 25886227

Group type: EXPERIMENTAL
Intervention: Ropivacaine with 8 mg dexamethasone (30 ml of 0.5% ropivacaine with 2 ml dexamethasone)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Ropivacaine alone (30 ml of 0.5% ropivacaine with 2 ml distilled water)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Ropivacaine with 8 mg dexamethasone
Number of subjects: 80

Group type: COMPARATOR
Intervention: Ropivacaine alone
Number of subjects: 80
Study: 23234472

Group type: EXPERIMENTAL
Intervention: Pressure-monitoring group (guidelines-based management with intraparenchymal intracranial pressure monitoring)
Number of subjects: 324

Group type: COMPARATOR
Intervention: Imaging-clinical examination group (treatment based on imaging and clinical examination)
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Pressure-monitoring group
Number of subjects: 324

Group type: COMPARATOR
Intervention: Imaging-clinical examination group
Number of subjects: 324
Study: 20688546

Group type: EXPERIMENTAL
Intervention: Noninvasive interactive neurostimulation device (InterX)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham device
Number of subjects: 60
Study: 19011441

Group type: EXPERIMENTAL
Intervention: Buprenorphine (BUP)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Methadone (MMP)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Perceived stress
Number of subjects: 59
Study: 15810908

Group type: EXPERIMENTAL
Intervention: BDDrFVIII (ReFacto) reconstituted with 5 mL of sterile water
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BDDrFVIII (ReFacto) reconstituted with 4 mL sodium chloride 0.9% USP
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hemofil M (plasma-derived, full-length FVIII preparation)
Number of subjects: 0
Study: 12860795

Group type: EXPERIMENTAL
Intervention: Patients with 1 or more typical lesions on MRI
Number of subjects: 388

Group type: COMPARATOR
Intervention: Patients with no lesions on MRI
Number of subjects: 388
Study: 10673175

Group type: EXPERIMENTAL
Intervention: Smoking cessation
Number of subjects: 3926

Group type: EXPERIMENTAL
Intervention: Sustained quitters
Number of subjects: 3926

Group type: COMPARATOR
Intervention: Continuing smokers
Number of subjects: 3926
Study: 8848333

Group type: EXPERIMENTAL
Intervention: ATP-MgCl2 (0.6 mumol/kg/min)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 14
Study: 1510256

Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway (LMA)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Tracheal intubation
Number of subjects: 41
Study: 6379574

Group type: EXPERIMENTAL
Intervention: Scrub A (chlorhexidine digluconate 40 mg/ml)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Scrub B (benzalkonium chloride 5 mg/ml)
Number of subjects: 113
Study: 30715489

Group type: EXPERIMENTAL
Intervention: mHealth-mediated exercise program (walking with a pedometer plus engagement in planned exercise supported by a mobile health application)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Active control condition (walking with a pedometer and exercise only)
Number of subjects: 51
Study: 28056569

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (MgSO4)
Number of subjects: 2241

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2241
Study: 27438687

Group type: EXPERIMENTAL
Intervention: Aripiprazole augmentation
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Base combined moderator (Mb*)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Full combined moderator (Mf*)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Placebo plus continuation venlafaxine monotherapy
Number of subjects: 159
Study: 25350473

Group type: EXPERIMENTAL
Intervention: Hydromorphone extended release (ER)
Number of subjects: 267

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 267
Study: 21843020

Group type: EXPERIMENTAL
Intervention: Participants who experienced success with a 24-hr rest interval
Number of subjects: 4

Group type: COMPARATOR
Intervention: Participants who did not feel successful or had a 5-min rest interval
Number of subjects: 4
Study: 19240707

Group type: EXPERIMENTAL
Intervention: Visilizumab (HuM291) 10 microg/kg intravenously on 2 consecutive days
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Visilizumab (HuM291)
Number of subjects: 34
Study: 17974123

Group type: EXPERIMENTAL
Intervention: Instillation of 5-aminolevulinic acid or hexyl aminolevulinate
Number of subjects: 0
Study: 15090103

Group type: EXPERIMENTAL
Intervention: Computer method for PTO elicitation
Number of subjects: 95

Group type: COMPARATOR
Intervention: Face-to-face interview method for PTO elicitation
Number of subjects: 95
Study: 11417612

Group type: EXPERIMENTAL
Intervention: Albendazole therapy
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 10023217

Group type: EXPERIMENTAL
Intervention: Laser-welded titanium frameworks
Number of subjects: 58

Group type: COMPARATOR
Intervention: Conventional cast frameworks
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 58
Study: 8200333

Group type: EXPERIMENTAL
Intervention: High fat diet (HF, 40.7 E%) during energy restriction
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Low fat diet (LF, 18.6 E%) during energy restriction
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Energy intake increase during P3
Number of subjects: 10

Group type: COMPARATOR
Intervention: Energy restriction
Number of subjects: 10
Study: 3336984

Group type: EXPERIMENTAL
Intervention: Intravenous metoprolol followed by oral metoprolol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 30695293

Group type: EXPERIMENTAL
Intervention: Valbenazine 40 mg/d
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Valbenazine 80 mg/d
Number of subjects: 202

Group type: COMPARATOR
Intervention: Valbenazine 40 and/or 80 mg/d
Number of subjects: 202
Study: 26940056

Group type: EXPERIMENTAL
Intervention: Higher reports of anxiety during the initial consultation
Number of subjects: 2891

Group type: EXPERIMENTAL
Intervention: Higher reports of depression during the initial consultation
Number of subjects: 2891
Study: 24381187

Group type: EXPERIMENTAL
Intervention: Aerosolized albuterol (intervention group)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 126
Study: 23777561

Group type: EXPERIMENTAL
Intervention: Green tea
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 20643425

Group type: EXPERIMENTAL
Intervention: 18-month behavioral weight loss intervention
Number of subjects: 338

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 338
Study: 18757465

Group type: EXPERIMENTAL
Intervention: Benign brain tumors patients (n=5)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Hippocampal sclerosis patients (n=9)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (n=14)
Number of subjects: 14
Study: 15851642

Group type: EXPERIMENTAL
Intervention: Chest radiography for detecting vertebral fractures
Number of subjects: 459

Group type: COMPARATOR
Intervention: Official radiologists' reports
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: History of osteoporosis
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: Osteoporosis medications
Number of subjects: 459
Study: 12439707

Group type: EXPERIMENTAL
Intervention: Docetaxel (100 mg m(‐2) every 3 weeks)
Number of subjects: 176

Group type: COMPARATOR
Intervention: 5-fluorouracil (750 mg m(‐2) per day continuous infusion D1-5) plus vinorelbine (25 mg m(‐2) D1 and D5 of each 3-week cycle
Number of subjects: 176
Study: 10490748

Group type: EXPERIMENTAL
Intervention: Computed Tomography (CT)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Panoramic Radiography
Number of subjects: 33
Study: 8604701

Group type: EXPERIMENTAL
Intervention: IgA probands with hypertension and/or progressive renal impairment
Number of subjects: 0

Group type: COMPARATOR
Intervention: First-degree relatives of patients with IgAN
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hypertensive relatives of IgAN patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IgA probands and their first-degree relatives
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Na/Li CT kinetics
Number of subjects: 0
Study: 2022561

Group type: EXPERIMENTAL
Intervention: recombinant DNA human GH (rhGH) 0.07 U/kg body wt daily for 6 months
Number of subjects: 24

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study: 7225166

Group type: EXPERIMENTAL
Intervention: Fenofibrate 400 mg/day
Number of subjects: 56

Group type: COMPARATOR
Intervention: Clofibate 2 g/day
Number of subjects: 56